[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJRGVzklDnvzAcIG4euqeNqbWbWIWrq8QLFAMndoaY4A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":83,"rows":90},"National University of Malaysia",[4],113,false,33,5,13316,16,70,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Pleural Effusion",3,{"name":18,"count":16},"Gestational Diabetes",{"name":20,"count":21},"Chronic Obstructive Pulmonary Disease",2,{"name":23,"count":21},"Pleural Infection",{"name":25,"count":21},"Trigger Finger",{"name":27,"count":21},"Type 2 Diabetes",{"name":29,"count":21},"Endophthalmitis Postoperative",{"name":31,"count":21},"Anxiety",[33,38,43,48,53,58,63,68,73,78],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06698484","To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed\u002FRefractory B- Non-Hodgkin Lymphoma (B-NHL)","2025-06-02","CAR-T cells",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06319560","Hydroxychloroquine in Type 2 Diabetes During Pregnancy","2026-06-01","Hydroxychloroquine Oral",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07407491","Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis","2026-07-08","Gentamicin - single dose",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06797882","Preventive Effects of Silver Diamine Fluoride on Early Enamel Caries","2026-08-31","Silver diamine fluoride- potassium iodide",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06377410","Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients","2026-11-30","Syrup Prospan",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03937544","Intravenous Autologous CD19 CAR-T Cells for R\u002FR B-ALL","2027-01-18","CD19 CAR-T CELLS",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06314620","Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency","2027-03-01","Heparin saline lock",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07362394","Autologous Dentine Graft Compared to Xenograft in Managing Periodontally Compromised Second Molar After Third Molar Removal","2027-11-30","Autologous dentin graft",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT07432373","Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection","2028-06-01","Intrapleural t-PA\u002FDnase arm",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06710717","Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)","2028-12-02","CD19 CAR-T cells",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,126,144,162,184,210,228,255,273,295,313,334,356,377,395,419,437,463,489,507,535,563,581,605,632,658,684,709,734,769,803,831,849,875,893,917,935,959,977,1005,1023,1041,1069,1087,1105,1123,1141,1167,1196,1233,1258,1283,1309,1339,1357,1375,1401,1426,1454,1472,1490,1513],{"intervention":62,"totalTrials":21,"cells":92},{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":107,"PHASE3":109,"PHASE4":122,"NA":124},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":106,"soonestReadout":81},[98],{"nctId":79,"briefTitle":80,"status":99,"phases":100,"primaryCompletion":81,"completion":101,"start":102,"enrollment":9,"conditions":103,"interventions":105},"RECRUITING",[85],"2029-01-02","2025-01-03",[104],"Systemic Lupus Erythematous (SLE)",[82],1,{"trials":108,"activeCount":95},[],{"trials":110,"activeCount":106,"soonestReadout":61},[111],{"nctId":59,"briefTitle":60,"status":99,"phases":112,"primaryCompletion":61,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},[86,87],"2027-03-18","2019-03-19",10,[117,118],"Relapsed B Acute Lymphoblastic Leukaemia","Refractory B Acute Lymphoblastic Leukaemia",[62,120,121],"Cyclophosphamide","Fludarabine",{"trials":123,"activeCount":95},[],{"trials":125,"activeCount":95},[],{"intervention":120,"totalTrials":106,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":140,"NA":142},{"trials":129,"activeCount":95},[],{"trials":131,"activeCount":95},[],{"trials":133,"activeCount":95},[],{"trials":135,"activeCount":106,"soonestReadout":61},[136],{"nctId":59,"briefTitle":60,"status":99,"phases":137,"primaryCompletion":61,"completion":113,"start":114,"enrollment":115,"conditions":138,"interventions":139},[86,87],[117,118],[62,120,121],{"trials":141,"activeCount":95},[],{"trials":143,"activeCount":95},[],{"intervention":121,"totalTrials":106,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":158,"NA":160},{"trials":147,"activeCount":95},[],{"trials":149,"activeCount":95},[],{"trials":151,"activeCount":95},[],{"trials":153,"activeCount":106,"soonestReadout":61},[154],{"nctId":59,"briefTitle":60,"status":99,"phases":155,"primaryCompletion":61,"completion":113,"start":114,"enrollment":115,"conditions":156,"interventions":157},[86,87],[117,118],[62,120,121],{"trials":159,"activeCount":95},[],{"trials":161,"activeCount":95},[],{"intervention":37,"totalTrials":106,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":178,"PHASE4":180,"NA":182},{"trials":165,"activeCount":95},[],{"trials":167,"activeCount":95},[],{"trials":169,"activeCount":106,"soonestReadout":36},[170],{"nctId":34,"briefTitle":35,"status":99,"phases":171,"primaryCompletion":36,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},[86],"2026-06-02","2021-06-03",20,[176],"Relapsed\u002FRefractory B- Cell Non-Hodgkin Lymphoma",[37],{"trials":179,"activeCount":95},[],{"trials":181,"activeCount":95},[],{"trials":183,"activeCount":95},[],{"intervention":47,"totalTrials":106,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":204,"PHASE4":206,"NA":208},{"trials":187,"activeCount":95},[],{"trials":189,"activeCount":95},[],{"trials":191,"activeCount":106,"soonestReadout":46},[192],{"nctId":44,"briefTitle":45,"status":99,"phases":193,"primaryCompletion":46,"completion":46,"start":194,"enrollment":195,"conditions":196,"interventions":202},[86],"2024-07-09",172,[197,198,199,200,201],"Acute Cholangitis","Biliary Tract Infection","Biliary Obstruction","Choledocholithiasis","Malignant Biliary Stricture",[47,203],"Distilled water",{"trials":205,"activeCount":95},[],{"trials":207,"activeCount":95},[],{"trials":209,"activeCount":95},[],{"intervention":203,"totalTrials":106,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":213,"activeCount":95},[],{"trials":215,"activeCount":95},[],{"trials":217,"activeCount":106,"soonestReadout":46},[218],{"nctId":44,"briefTitle":45,"status":99,"phases":219,"primaryCompletion":46,"completion":46,"start":194,"enrollment":195,"conditions":220,"interventions":221},[86],[197,198,199,200,201],[47,203],{"trials":223,"activeCount":95},[],{"trials":225,"activeCount":95},[],{"trials":227,"activeCount":95},[],{"intervention":52,"totalTrials":106,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":231,"activeCount":95},[],{"trials":233,"activeCount":95},[],{"trials":235,"activeCount":106,"soonestReadout":51},[236],{"nctId":49,"briefTitle":50,"status":237,"phases":238,"primaryCompletion":51,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":247},"NOT_YET_RECRUITING",[86],"2026-12-31","2025-01-31",99,[243,244,245,246],"Demineralization, Tooth","White Spot Lesion of Tooth","Fixed Appliances","Early Caries Lesions",[52,248],"Fluoride varnish",{"trials":250,"activeCount":95},[],{"trials":252,"activeCount":95},[],{"trials":254,"activeCount":95},[],{"intervention":248,"totalTrials":106,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":267,"PHASE4":269,"NA":271},{"trials":258,"activeCount":95},[],{"trials":260,"activeCount":95},[],{"trials":262,"activeCount":106,"soonestReadout":51},[263],{"nctId":49,"briefTitle":50,"status":237,"phases":264,"primaryCompletion":51,"completion":239,"start":240,"enrollment":241,"conditions":265,"interventions":266},[86],[243,244,245,246],[52,248],{"trials":268,"activeCount":95},[],{"trials":270,"activeCount":95},[],{"trials":272,"activeCount":95},[],{"intervention":77,"totalTrials":106,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":276,"activeCount":95},[],{"trials":278,"activeCount":95},[],{"trials":280,"activeCount":95},[],{"trials":282,"activeCount":95},[],{"trials":284,"activeCount":95},[],{"trials":286,"activeCount":106,"soonestReadout":76},[287],{"nctId":74,"briefTitle":75,"status":237,"phases":288,"primaryCompletion":76,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":293},[],"2028-07-01","2026-04-01",80,[23],[77,294],"t-PA (Alteplase) 5-10mg and Tyloxapol 200mg",{"intervention":294,"totalTrials":106,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":307},{"trials":298,"activeCount":95},[],{"trials":300,"activeCount":95},[],{"trials":302,"activeCount":95},[],{"trials":304,"activeCount":95},[],{"trials":306,"activeCount":95},[],{"trials":308,"activeCount":106,"soonestReadout":76},[309],{"nctId":74,"briefTitle":75,"status":237,"phases":310,"primaryCompletion":76,"completion":289,"start":290,"enrollment":291,"conditions":311,"interventions":312},[],[23],[77,294],{"intervention":67,"totalTrials":106,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":325},{"trials":316,"activeCount":95},[],{"trials":318,"activeCount":95},[],{"trials":320,"activeCount":95},[],{"trials":322,"activeCount":95},[],{"trials":324,"activeCount":95},[],{"trials":326,"activeCount":106,"soonestReadout":66},[327],{"nctId":64,"briefTitle":65,"status":99,"phases":328,"primaryCompletion":66,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":333},[89],"2027-06-01","2024-03-15",40,[15],[67],{"intervention":42,"totalTrials":106,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":337,"activeCount":95},[],{"trials":339,"activeCount":95},[],{"trials":341,"activeCount":95},[],{"trials":343,"activeCount":95},[],{"trials":345,"activeCount":95},[],{"trials":347,"activeCount":106,"soonestReadout":41},[348],{"nctId":39,"briefTitle":40,"status":99,"phases":349,"primaryCompletion":41,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":355},[89],"2027-01-01","2024-03-24",56,[354,27],"Diabetes in Pregnancy",[42],{"intervention":57,"totalTrials":106,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":368},{"trials":359,"activeCount":95},[],{"trials":361,"activeCount":95},[],{"trials":363,"activeCount":95},[],{"trials":365,"activeCount":95},[],{"trials":367,"activeCount":95},[],{"trials":369,"activeCount":106,"soonestReadout":56},[370],{"nctId":54,"briefTitle":55,"status":99,"phases":371,"primaryCompletion":56,"completion":56,"start":372,"enrollment":373,"conditions":374,"interventions":375},[89],"2024-05-01",100,[20],[57,376],"N-Acetylcysteine",{"intervention":376,"totalTrials":106,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":380,"activeCount":95},[],{"trials":382,"activeCount":95},[],{"trials":384,"activeCount":95},[],{"trials":386,"activeCount":95},[],{"trials":388,"activeCount":95},[],{"trials":390,"activeCount":106,"soonestReadout":56},[391],{"nctId":54,"briefTitle":55,"status":99,"phases":392,"primaryCompletion":56,"completion":56,"start":372,"enrollment":373,"conditions":393,"interventions":394},[89],[20],[57,376],{"intervention":72,"totalTrials":106,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":407},{"trials":398,"activeCount":95},[],{"trials":400,"activeCount":95},[],{"trials":402,"activeCount":95},[],{"trials":404,"activeCount":95},[],{"trials":406,"activeCount":95},[],{"trials":408,"activeCount":106,"soonestReadout":71},[409],{"nctId":69,"briefTitle":70,"status":237,"phases":410,"primaryCompletion":71,"completion":411,"start":41,"enrollment":412,"conditions":413,"interventions":418},[89],"2028-06-30",34,[414,415,416,417],"Impacted Mandibular Third Molar Extraction","Dentin Graft","Xenograft","Bone Defects",[72,416],{"intervention":416,"totalTrials":106,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":422,"activeCount":95},[],{"trials":424,"activeCount":95},[],{"trials":426,"activeCount":95},[],{"trials":428,"activeCount":95},[],{"trials":430,"activeCount":95},[],{"trials":432,"activeCount":106,"soonestReadout":71},[433],{"nctId":69,"briefTitle":70,"status":237,"phases":434,"primaryCompletion":71,"completion":411,"start":41,"enrollment":412,"conditions":435,"interventions":436},[89],[414,415,416,417],[72,416],{"intervention":438,"totalTrials":106,"cells":439},"Hyoscine Butylbromide",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":461},{"trials":441,"activeCount":95},[],{"trials":443,"activeCount":95},[],{"trials":445,"activeCount":95},[],{"trials":447,"activeCount":95},[],{"trials":449,"activeCount":95},[450],{"nctId":451,"briefTitle":452,"status":453,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":460},"NCT04349722","The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae","COMPLETED",[88],"2020-06-30","2019-12-01",110,[459],"Labor Long",[438],{"trials":462,"activeCount":95},[],{"intervention":464,"totalTrials":106,"cells":465},"Ketamine-Morphine",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":487},{"trials":467,"activeCount":95},[],{"trials":469,"activeCount":95},[],{"trials":471,"activeCount":95},[],{"trials":473,"activeCount":95},[],{"trials":475,"activeCount":95},[476],{"nctId":477,"briefTitle":478,"status":453,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":486},"NCT06010056","PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.",[88],"2019-04-04","2018-04-05",60,[484,485],"Ketamine","Morphine",[464,485],{"trials":488,"activeCount":95},[],{"intervention":485,"totalTrials":106,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":505},{"trials":492,"activeCount":95},[],{"trials":494,"activeCount":95},[],{"trials":496,"activeCount":95},[],{"trials":498,"activeCount":95},[],{"trials":500,"activeCount":95},[501],{"nctId":477,"briefTitle":478,"status":453,"phases":502,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":503,"interventions":504},[88],[484,485],[464,485],{"trials":506,"activeCount":95},[],{"intervention":508,"totalTrials":106,"cells":509},"Ambroxol Hydrochloride",{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":533},{"trials":511,"activeCount":95},[],{"trials":513,"activeCount":95},[],{"trials":515,"activeCount":95},[],{"trials":517,"activeCount":95},[],{"trials":519,"activeCount":95},[520],{"nctId":521,"briefTitle":522,"status":453,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":532},"NCT05663905","Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients",[88],"2023-10-31","2023-01-07",32,[528,529,530,531],"Severe Pneumonia","Community-acquired Pneumonia","Hospital-acquired Pneumonia","Critical Illness",[508],{"trials":534,"activeCount":95},[],{"intervention":536,"totalTrials":106,"cells":537},"Oral Colchicine 0.6 mg",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":561},{"trials":539,"activeCount":95},[],{"trials":541,"activeCount":95},[],{"trials":543,"activeCount":95},[],{"trials":545,"activeCount":95},[],{"trials":547,"activeCount":95},[548],{"nctId":549,"briefTitle":550,"status":551,"phases":552,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":559},"NCT06020300","Short Course Low Dose Oral Colchicine After ST Elevation Myocardial Infarction(STEMI)","UNKNOWN",[88],"2023-12-29","2024-05-31","2023-07-28",64,[558],"STEMI",[536,560],"Oral Pyridoxine 10 mg",{"trials":562,"activeCount":95},[],{"intervention":560,"totalTrials":106,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":573,"NA":579},{"trials":566,"activeCount":95},[],{"trials":568,"activeCount":95},[],{"trials":570,"activeCount":95},[],{"trials":572,"activeCount":95},[],{"trials":574,"activeCount":95},[575],{"nctId":549,"briefTitle":550,"status":551,"phases":576,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":577,"interventions":578},[88],[558],[536,560],{"trials":580,"activeCount":95},[],{"intervention":582,"totalTrials":106,"cells":583},"Fondaparinux 2.5Mg\u002F0.5Ml Inj Syr",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":603},{"trials":585,"activeCount":95},[],{"trials":587,"activeCount":95},[],{"trials":589,"activeCount":95},[],{"trials":591,"activeCount":95},[],{"trials":593,"activeCount":95},[594],{"nctId":595,"briefTitle":596,"status":453,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":482,"conditions":600,"interventions":602},"NCT04447378","Safety of Fondaparinux as Post Partum Thromboprophylaxis",[88],"2018-06-01","2017-09-01",[601],"Thromboembolism in the Puerperium",[582],{"trials":604,"activeCount":95},[],{"intervention":606,"totalTrials":106,"cells":607},"Empagliflozin 25 MG",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":630},{"trials":609,"activeCount":95},[],{"trials":611,"activeCount":95},[],{"trials":613,"activeCount":95},[],{"trials":615,"activeCount":95},[],{"trials":617,"activeCount":95},[618],{"nctId":619,"briefTitle":620,"status":551,"phases":621,"primaryCompletion":622,"completion":623,"start":456,"enrollment":624,"conditions":625,"interventions":629},"NCT04215445","Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD",[88],"2020-05","2020-08",90,[626,627,628],"Diabetic Retinopathy","Chronic Kidney Diseases","Diabetes Mellitus",[606],{"trials":631,"activeCount":95},[],{"intervention":633,"totalTrials":106,"cells":634},"ultrasound-guided transversals fascia plane block with ropivacaine",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":643,"NA":656},{"trials":636,"activeCount":95},[],{"trials":638,"activeCount":95},[],{"trials":640,"activeCount":95},[],{"trials":642,"activeCount":95},[],{"trials":644,"activeCount":95},[645],{"nctId":646,"briefTitle":647,"status":453,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":526,"conditions":651,"interventions":655},"NCT06883370","Analgesia Evaluation of an Ultrasound-guided Technique for Inguinal Hernia Surgery in Children in Children",[88],"2024-11-30","2023-12-01",[652,653,654],"Inguinal Hernia","Surgery","Paediatric",[633],{"trials":657,"activeCount":95},[],{"intervention":659,"totalTrials":106,"cells":660},"Tocotrienol-rich fraction vitamin E",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":682},{"trials":662,"activeCount":95},[],{"trials":664,"activeCount":95},[],{"trials":666,"activeCount":95},[],{"trials":668,"activeCount":95},[],{"trials":670,"activeCount":95},[671],{"nctId":672,"briefTitle":673,"status":453,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":681},"NCT05905185","Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity",[88],"2022-01-01","2022-01-21","2020-01-01",29,[680],"Obesity",[659],{"trials":683,"activeCount":95},[],{"intervention":685,"totalTrials":106,"cells":686},"Micronised vaginal progesterone",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":705,"NA":707},{"trials":688,"activeCount":95},[],{"trials":690,"activeCount":95},[],{"trials":692,"activeCount":95},[],{"trials":694,"activeCount":95},[695],{"nctId":696,"briefTitle":697,"status":453,"phases":698,"primaryCompletion":699,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":704},"NCT04342585","Comparison Between Vaginal Pessary and Progestogen in Twin Pregnancy With Short Cervical Length",[87],"2022-09-30","2019-10-01",142,[703],"Preterm Birth",[685],{"trials":706,"activeCount":95},[],{"trials":708,"activeCount":95},[],{"intervention":710,"totalTrials":106,"cells":711},"Dipeptidyl-Peptidase IV Inhibitors",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":730,"NA":732},{"trials":713,"activeCount":95},[],{"trials":715,"activeCount":95},[],{"trials":717,"activeCount":95},[],{"trials":719,"activeCount":95},[720],{"nctId":721,"briefTitle":722,"status":453,"phases":723,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT05290506","Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus",[87],"2021-03-01","2020-08-01",50,[728,27],"PreDiabetes",[710],{"trials":731,"activeCount":95},[],{"trials":733,"activeCount":95},[],{"intervention":735,"totalTrials":21,"cells":736},"Autologous bone marrow-derived mesenchymal stem cells",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":738,"activeCount":95},[],{"trials":740,"activeCount":95},[],{"trials":742,"activeCount":95},[743,753],{"nctId":744,"briefTitle":745,"status":551,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":726,"conditions":750,"interventions":752},"NCT01461720","Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct",[86],"2015-12","2016-03","2012-03",[751],"Middle Cerebral Artery Infarction",[735],{"nctId":754,"briefTitle":755,"status":551,"phases":756,"primaryCompletion":757,"completion":757,"start":758,"enrollment":726,"conditions":759,"interventions":761},"NCT01459640","Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis",[86],"2014-03","2011-03",[760],"Osteoarthritis",[762,735],"Hyaluronic Acid",{"trials":764,"activeCount":95},[],{"trials":766,"activeCount":95},[],{"trials":768,"activeCount":95},[],{"intervention":770,"totalTrials":21,"cells":771},"Moxifloxacin Ophthalmic Solution",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":797,"PHASE4":799,"NA":801},{"trials":773,"activeCount":95},[],{"trials":775,"activeCount":95},[],{"trials":777,"activeCount":95},[778,790],{"nctId":779,"briefTitle":780,"status":551,"phases":781,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":788},"NCT04214821","The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%",[85,86],"2021-08","2022-05","2019-09-23",128,[787],"Endophthalmitis",[789,770],"Levofloxacin Ophthalmic Solution",{"nctId":791,"briefTitle":792,"status":551,"phases":793,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":794,"interventions":795},"NCT04212429","The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%",[85,86],[29],[796,770],"Levofloxacin Ophthalmic Product",{"trials":798,"activeCount":95},[],{"trials":800,"activeCount":95},[],{"trials":802,"activeCount":95},[],{"intervention":804,"totalTrials":106,"cells":805},"Gemeprost 1 Mg Vaginal Pessary",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":807,"activeCount":95},[],{"trials":809,"activeCount":95},[],{"trials":811,"activeCount":95},[812],{"nctId":813,"briefTitle":814,"status":453,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":823},"NCT05342467","Gemeprost Versus Dinoprostone in First Trimester Miscarriages",[86],"2024-10-28","2022-11-11",101,[820,821,822],"Missed Abortion","Medical; Abortion, Fetus","Incomplete Abortion",[804,824],"Dinoprostone 3 mg",{"trials":826,"activeCount":95},[],{"trials":828,"activeCount":95},[],{"trials":830,"activeCount":95},[],{"intervention":824,"totalTrials":106,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":834,"activeCount":95},[],{"trials":836,"activeCount":95},[],{"trials":838,"activeCount":95},[839],{"nctId":813,"briefTitle":814,"status":453,"phases":840,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":841,"interventions":842},[86],[820,821,822],[804,824],{"trials":844,"activeCount":95},[],{"trials":846,"activeCount":95},[],{"trials":848,"activeCount":95},[],{"intervention":850,"totalTrials":106,"cells":851},"Levofloxacin Ophthalmic",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":853,"activeCount":95},[],{"trials":855,"activeCount":95},[],{"trials":857,"activeCount":95},[858],{"nctId":859,"briefTitle":860,"status":551,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":867},"NCT04212078","Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime",[85,86],"2022-01","2022-10","2019-07-29",138,[29],[850,868],"Cefuroxime",{"trials":870,"activeCount":95},[],{"trials":872,"activeCount":95},[],{"trials":874,"activeCount":95},[],{"intervention":868,"totalTrials":106,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":878,"activeCount":95},[],{"trials":880,"activeCount":95},[],{"trials":882,"activeCount":95},[883],{"nctId":859,"briefTitle":860,"status":551,"phases":884,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":885,"interventions":886},[85,86],[29],[850,868],{"trials":888,"activeCount":95},[],{"trials":890,"activeCount":95},[],{"trials":892,"activeCount":95},[],{"intervention":894,"totalTrials":106,"cells":895},"Probiotic",{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":897,"activeCount":95},[],{"trials":899,"activeCount":95},[],{"trials":901,"activeCount":95},[902],{"nctId":903,"briefTitle":904,"status":453,"phases":905,"primaryCompletion":906,"completion":906,"start":700,"enrollment":907,"conditions":908,"interventions":910},"NCT04119011","Probiotics in Women With Primary Dysmenorrhoea",[85,86],"2020-03-31",72,[909],"Primary Dysmenorrhea",[894],{"trials":912,"activeCount":95},[],{"trials":914,"activeCount":95},[],{"trials":916,"activeCount":95},[],{"intervention":789,"totalTrials":106,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":920,"activeCount":95},[],{"trials":922,"activeCount":95},[],{"trials":924,"activeCount":95},[925],{"nctId":779,"briefTitle":780,"status":551,"phases":926,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":927,"interventions":928},[85,86],[787],[789,770],{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":95},[],{"trials":934,"activeCount":95},[],{"intervention":936,"totalTrials":106,"cells":937},"Mononuclear and mesenchymal stem cells",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":953,"PHASE4":955,"NA":957},{"trials":939,"activeCount":95},[],{"trials":941,"activeCount":95},[],{"trials":943,"activeCount":95},[944],{"nctId":945,"briefTitle":946,"status":551,"phases":947,"primaryCompletion":747,"completion":948,"start":758,"enrollment":726,"conditions":949,"interventions":951},"NCT01456819","Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia",[86],"2016-02",[950],"Critical Limb Ischemia",[936,952],"Mononuclear cells",{"trials":954,"activeCount":95},[],{"trials":956,"activeCount":95},[],{"trials":958,"activeCount":95},[],{"intervention":952,"totalTrials":106,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":962,"activeCount":95},[],{"trials":964,"activeCount":95},[],{"trials":966,"activeCount":95},[967],{"nctId":945,"briefTitle":946,"status":551,"phases":968,"primaryCompletion":747,"completion":948,"start":758,"enrollment":726,"conditions":969,"interventions":970},[86],[950],[936,952],{"trials":972,"activeCount":95},[],{"trials":974,"activeCount":95},[],{"trials":976,"activeCount":95},[],{"intervention":484,"totalTrials":106,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":980,"activeCount":95},[],{"trials":982,"activeCount":95},[],{"trials":984,"activeCount":95},[985],{"nctId":986,"briefTitle":987,"status":453,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":624,"conditions":992,"interventions":996},"NCT06111872","Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.",[86],"2024-02-27","2024-10-25","2023-07-18",[993,994,200,995],"Cholangitis","Pancreatic Cancer","Choledochal Cyst",[484,997,998],"Midazolam","Pethidin",{"trials":1000,"activeCount":95},[],{"trials":1002,"activeCount":95},[],{"trials":1004,"activeCount":95},[],{"intervention":997,"totalTrials":106,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":1008,"activeCount":95},[],{"trials":1010,"activeCount":95},[],{"trials":1012,"activeCount":95},[1013],{"nctId":986,"briefTitle":987,"status":453,"phases":1014,"primaryCompletion":989,"completion":990,"start":991,"enrollment":624,"conditions":1015,"interventions":1016},[86],[993,994,200,995],[484,997,998],{"trials":1018,"activeCount":95},[],{"trials":1020,"activeCount":95},[],{"trials":1022,"activeCount":95},[],{"intervention":998,"totalTrials":106,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":95},[],{"trials":1028,"activeCount":95},[],{"trials":1030,"activeCount":95},[1031],{"nctId":986,"briefTitle":987,"status":453,"phases":1032,"primaryCompletion":989,"completion":990,"start":991,"enrollment":624,"conditions":1033,"interventions":1034},[86],[993,994,200,995],[484,997,998],{"trials":1036,"activeCount":95},[],{"trials":1038,"activeCount":95},[],{"trials":1040,"activeCount":95},[],{"intervention":1042,"totalTrials":106,"cells":1043},"Optive, Ophthalmic Solution",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1045,"activeCount":95},[],{"trials":1047,"activeCount":95},[],{"trials":1049,"activeCount":95},[1050],{"nctId":1051,"briefTitle":1052,"status":551,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":1057,"conditions":1058,"interventions":1060},"NCT04217785","Umbilical Cord Serum Versus Conventional Eyedrops",[85,86],"2020-12","2021-05","2020-01-20",102,[1059],"Dry Eye Syndromes",[1042,1061,1062],"Umbilical Cord Serum eye drops","Genteal lubricant gel",{"trials":1064,"activeCount":95},[],{"trials":1066,"activeCount":95},[],{"trials":1068,"activeCount":95},[],{"intervention":1061,"totalTrials":106,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1072,"activeCount":95},[],{"trials":1074,"activeCount":95},[],{"trials":1076,"activeCount":95},[1077],{"nctId":1051,"briefTitle":1052,"status":551,"phases":1078,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":1057,"conditions":1079,"interventions":1080},[85,86],[1059],[1042,1061,1062],{"trials":1082,"activeCount":95},[],{"trials":1084,"activeCount":95},[],{"trials":1086,"activeCount":95},[],{"intervention":1062,"totalTrials":106,"cells":1088},{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1090,"activeCount":95},[],{"trials":1092,"activeCount":95},[],{"trials":1094,"activeCount":95},[1095],{"nctId":1051,"briefTitle":1052,"status":551,"phases":1096,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":1057,"conditions":1097,"interventions":1098},[85,86],[1059],[1042,1061,1062],{"trials":1100,"activeCount":95},[],{"trials":1102,"activeCount":95},[],{"trials":1104,"activeCount":95},[],{"intervention":762,"totalTrials":106,"cells":1106},{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1117,"PHASE4":1119,"NA":1121},{"trials":1108,"activeCount":95},[],{"trials":1110,"activeCount":95},[],{"trials":1112,"activeCount":95},[1113],{"nctId":754,"briefTitle":755,"status":551,"phases":1114,"primaryCompletion":757,"completion":757,"start":758,"enrollment":726,"conditions":1115,"interventions":1116},[86],[760],[762,735],{"trials":1118,"activeCount":95},[],{"trials":1120,"activeCount":95},[],{"trials":1122,"activeCount":95},[],{"intervention":796,"totalTrials":106,"cells":1124},{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1126,"activeCount":95},[],{"trials":1128,"activeCount":95},[],{"trials":1130,"activeCount":95},[1131],{"nctId":791,"briefTitle":792,"status":551,"phases":1132,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":1133,"interventions":1134},[85,86],[29],[796,770],{"trials":1136,"activeCount":95},[],{"trials":1138,"activeCount":95},[],{"trials":1140,"activeCount":95},[],{"intervention":1142,"totalTrials":106,"cells":1143},"Placebos",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1159,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[1148],{"nctId":1149,"briefTitle":1150,"status":551,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":373,"conditions":1154,"interventions":1158},"NCT04164446","Supplementation of Oil Palm Phenolics to Healthy Participants",[85],"2020-04","2019-12-16",[1155,1156,1157],"Cardiovascular Diseases","Hyperlipidemias","Hypercholesterolemia",[1142],{"trials":1160,"activeCount":95},[],{"trials":1162,"activeCount":95},[],{"trials":1164,"activeCount":95},[],{"trials":1166,"activeCount":95},[],{"intervention":1168,"totalTrials":106,"cells":1169},"Dydrogesterone Pill",{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1171,"activeCount":95},[],{"trials":1173,"activeCount":95},[1174],{"nctId":1175,"briefTitle":1176,"status":453,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1187},"NCT04175990","IVF Outcome Following Progestogen Ovarian Stimulation",[85],"2019-03-10","2019-05-09","2018-05-10",155,[1183,1184,1185,1186],"IVF","Oocyte Maturation Defect 1","Clinical Pregnancy Rate","Ovarian Hyperstimulation",[1168],{"trials":1189,"activeCount":95},[],{"trials":1191,"activeCount":95},[],{"trials":1193,"activeCount":95},[],{"trials":1195,"activeCount":95},[],{"intervention":1197,"totalTrials":21,"cells":1198},"Nasonex Nasal Spray",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1200,"activeCount":95},[],{"trials":1202,"activeCount":95},[],{"trials":1204,"activeCount":95},[],{"trials":1206,"activeCount":95},[],{"trials":1208,"activeCount":95},[],{"trials":1210,"activeCount":95},[1211,1222],{"nctId":1212,"briefTitle":1213,"status":453,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1221},"NCT05919316","The Efficacy Of Rhinophototherapy Compared To Intranasal Corticosteroids On The Nasal Mucosa",[89],"2024-10-10","2024-11-10","2023-07-04",35,[1220],"Allergic Rhinitis",[1197],{"nctId":1223,"briefTitle":1224,"status":453,"phases":1225,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1230},"NCT05912192","The Efficacy Of Elonide Nasal Corticosteroids In Managing Allergic Rhinitis",[89],"2023-04-14","2022-02-24",163,[1220],[1231,1197,1232],"Elonide Nasal Spray","Normal saline",{"intervention":1234,"totalTrials":106,"cells":1235},"utrogestan",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1237,"activeCount":95},[],{"trials":1239,"activeCount":95},[],{"trials":1241,"activeCount":95},[],{"trials":1243,"activeCount":95},[],{"trials":1245,"activeCount":95},[],{"trials":1247,"activeCount":95},[1248],{"nctId":1249,"briefTitle":1250,"status":551,"phases":1251,"primaryCompletion":1252,"completion":1253,"start":1254,"enrollment":331,"conditions":1255,"interventions":1257},"NCT04175002","Endometrial Heparin-binding Epidermal Growth Factor Expression",[],"2020-05-31","2020-07-31","2019-08-01",[1256],"Gene Abnormality",[1234],{"intervention":1259,"totalTrials":106,"cells":1260},"Eleveld Model",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1262,"activeCount":95},[],{"trials":1264,"activeCount":95},[],{"trials":1266,"activeCount":95},[],{"trials":1268,"activeCount":95},[],{"trials":1270,"activeCount":95},[],{"trials":1272,"activeCount":95},[1273],{"nctId":1274,"briefTitle":1275,"status":551,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":526,"conditions":1280,"interventions":1282},"NCT05885100","Prospective Validation Of The Eleveld TCI Model For Propofol In The Malaysian Obese Population",[89],"2025-11-30","2025-12-31","2023-06-01",[1281],"Total Intravenous Anaesthesia, Eleveld Model, Obes",[1259],{"intervention":1284,"totalTrials":106,"cells":1285},"Decapeptyl 0.2mg",{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1287,"activeCount":95},[],{"trials":1289,"activeCount":95},[],{"trials":1291,"activeCount":95},[],{"trials":1293,"activeCount":95},[],{"trials":1295,"activeCount":95},[],{"trials":1297,"activeCount":95},[1298],{"nctId":1299,"briefTitle":1300,"status":453,"phases":1301,"primaryCompletion":1302,"completion":1303,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1308},"NCT04174378","Luteal Phase Support In IVF Women Using GnRH Agonist",[],"2019-08-28","2019-11-18","2018-11-29",222,[1183,1307],"Luteal Phase Defect",[1284],{"intervention":1310,"totalTrials":106,"cells":1311},"Eradication therapy for H.pylori infection",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1320,"NA":1322},{"trials":1313,"activeCount":95},[],{"trials":1315,"activeCount":95},[],{"trials":1317,"activeCount":95},[],{"trials":1319,"activeCount":95},[],{"trials":1321,"activeCount":95},[],{"trials":1323,"activeCount":95},[1324],{"nctId":1325,"briefTitle":1326,"status":453,"phases":1327,"primaryCompletion":1328,"completion":1329,"start":1330,"enrollment":1331,"conditions":1332,"interventions":1336},"NCT02112812","Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease",[89],"2013-03","2013-04","2012-12",82,[1333,1334,1335],"Response to Levodopa","Motor Outcomes","Quality of Life Outcomes",[1310,1337,1338],"Eradication of Helcobacter Pylori","Eradication therapy for Helicobacter pylori",{"intervention":1337,"totalTrials":106,"cells":1340},{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1342,"activeCount":95},[],{"trials":1344,"activeCount":95},[],{"trials":1346,"activeCount":95},[],{"trials":1348,"activeCount":95},[],{"trials":1350,"activeCount":95},[],{"trials":1352,"activeCount":95},[1353],{"nctId":1325,"briefTitle":1326,"status":453,"phases":1354,"primaryCompletion":1328,"completion":1329,"start":1330,"enrollment":1331,"conditions":1355,"interventions":1356},[89],[1333,1334,1335],[1310,1337,1338],{"intervention":1338,"totalTrials":106,"cells":1358},{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1360,"activeCount":95},[],{"trials":1362,"activeCount":95},[],{"trials":1364,"activeCount":95},[],{"trials":1366,"activeCount":95},[],{"trials":1368,"activeCount":95},[],{"trials":1370,"activeCount":95},[1371],{"nctId":1325,"briefTitle":1326,"status":453,"phases":1372,"primaryCompletion":1328,"completion":1329,"start":1330,"enrollment":1331,"conditions":1373,"interventions":1374},[89],[1333,1334,1335],[1310,1337,1338],{"intervention":1376,"totalTrials":106,"cells":1377},"Sitagliptin",{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1379,"activeCount":95},[],{"trials":1381,"activeCount":95},[],{"trials":1383,"activeCount":95},[],{"trials":1385,"activeCount":95},[],{"trials":1387,"activeCount":95},[],{"trials":1389,"activeCount":95},[1390],{"nctId":1391,"briefTitle":1392,"status":453,"phases":1393,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1400},"NCT03659461","Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus",[89],"2019-12-31","2020-01-31","2017-10-01",174,[1399,728],"Type 2 Diabetes Mellitus",[1376],{"intervention":1402,"totalTrials":106,"cells":1403},"Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg",{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1405,"activeCount":95},[],{"trials":1407,"activeCount":95},[],{"trials":1409,"activeCount":95},[],{"trials":1411,"activeCount":95},[],{"trials":1413,"activeCount":95},[],{"trials":1415,"activeCount":95},[1416],{"nctId":1417,"briefTitle":1418,"status":453,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT04915586","Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management",[89],"2020-12-31","2019-12-30",30,[1424],"Loculated Empyema",[1402],{"intervention":1427,"totalTrials":106,"cells":1428},"cumulus cell oocytes complex (COC) among women with poor ovarian reserve",{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1430,"activeCount":95},[],{"trials":1432,"activeCount":95},[],{"trials":1434,"activeCount":95},[],{"trials":1436,"activeCount":95},[],{"trials":1438,"activeCount":95},[],{"trials":1440,"activeCount":95},[1441],{"nctId":1442,"briefTitle":1443,"status":551,"phases":1444,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":1422,"conditions":1448,"interventions":1453},"NCT06315777","GREM1, HAS2 and PTGS2 Gene Expression Following the in Vitro Maturation (IVM)",[89],"2024-07-01","2024-07-31","2021-07-01",[1449,1450,1451,1452],"Increased Oocyte Death","in Vitro Maturation","GREM1 Gene Mutation","Cumulus Cell",[1427],{"intervention":1231,"totalTrials":106,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1457,"activeCount":95},[],{"trials":1459,"activeCount":95},[],{"trials":1461,"activeCount":95},[],{"trials":1463,"activeCount":95},[],{"trials":1465,"activeCount":95},[],{"trials":1467,"activeCount":95},[1468],{"nctId":1223,"briefTitle":1224,"status":453,"phases":1469,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":1228,"conditions":1470,"interventions":1471},[89],[1220],[1231,1197,1232],{"intervention":1232,"totalTrials":106,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1475,"activeCount":95},[],{"trials":1477,"activeCount":95},[],{"trials":1479,"activeCount":95},[],{"trials":1481,"activeCount":95},[],{"trials":1483,"activeCount":95},[],{"trials":1485,"activeCount":95},[1486],{"nctId":1223,"briefTitle":1224,"status":453,"phases":1487,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":1228,"conditions":1488,"interventions":1489},[89],[1220],[1231,1197,1232],{"intervention":1491,"totalTrials":106,"cells":1492},"Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg",{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1499,"PHASE4":1501,"NA":1503},{"trials":1494,"activeCount":95},[],{"trials":1496,"activeCount":95},[],{"trials":1498,"activeCount":95},[],{"trials":1500,"activeCount":95},[],{"trials":1502,"activeCount":95},[],{"trials":1504,"activeCount":95},[1505],{"nctId":1506,"briefTitle":1507,"status":453,"phases":1508,"primaryCompletion":1509,"completion":1509,"start":1510,"enrollment":331,"conditions":1511,"interventions":1512},"NCT05903417","Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic",[89],"2025-10-14","2023-07-10",[23],[1491],{"intervention":1514,"totalTrials":106,"cells":1515},"DSPP level in GCF",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1517,"activeCount":95},[],{"trials":1519,"activeCount":95},[],{"trials":1521,"activeCount":95},[],{"trials":1523,"activeCount":95},[],{"trials":1525,"activeCount":95},[],{"trials":1527,"activeCount":95},[1528],{"nctId":1529,"briefTitle":1530,"status":453,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1422,"conditions":1535,"interventions":1537},"NCT05077878","Analysis of Dentine Sialophosphoprotein (DSPP) for Root Resorption",[],"2019-12-14","2020-03-12","2018-09-14",[1536],"Root Resorption",[1514]]